Learn / NVS
NYSE: NVS
Novartis AG (NVS) stock, explained like you're 5
Novartis is a giant Swiss drug company. It invents, makes, and sells prescription medicines for serious illnesses like cancer, heart disease, and conditions that affect the brain and immune system. Think of it as a lab that spends years turning science into pills and treatments that doctors prescribe to patients around the world.
- Ticker
- NVS
- Exchange
- New York Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Size
- Mega cap, about 274.3 billion dollars
- Led by
- Vasant Narasimhan
- Headquarters
- Basel, BS, CH
- Employees
- 75,267
- Public since
- 1996
Is Novartis AG a small, medium or large cap company?
Yes. Novartis AG is a large cap stock, and an extra big one: it is a mega cap, worth more than 200 billion dollars. Its market cap, which is the total value of all its shares, is about 274.3 billion dollars.
Here is how you can tell. Multiply the share price by the number of shares to get the market cap, then compare it to the usual sizes. Micro cap is under 300 million dollars, small cap is 300 million to 2 billion, mid cap is 2 to 10 billion, large cap is 10 billion and up, and mega cap is over 200 billion. Market caps move every day with the share price, so treat the number as a recent snapshot.
How Novartis AG makes money
- Selling innovative prescription medicines across four core areas: oncology (cancer), immunology, neuroscience, and cardiovascular diseases.
- Revenue from established, older branded medicines that still hold market share even after their original patent protection has expired.
- Selling specialized therapies for rarer or more complex conditions, which often command higher prices due to limited treatment alternatives.
- Generating royalties and licensing income when other companies use Novartis developed compounds or technology under formal agreements.
What moves NVS stock
- Clinical trial results: when a key drug succeeds or fails in trials, the stock can move sharply because future revenue depends on a healthy pipeline of new medicines.
- Patent cliffs: when a top selling Novartis drug loses its patent, cheaper generic versions flood the market and can cut that drug's revenue fast.
- Regulatory decisions from bodies like the US FDA, which can approve or reject new drugs and directly affect how much money Novartis can make from years of research spending.
- Currency swings: Novartis earns revenue across many countries but reports in US dollars, so a stronger dollar can make overseas sales look smaller even if nothing changed in the business.
Good to know about Novartis AG
- Novartis was founded on 29 February 1996 and is headquartered in Basel, Switzerland, one of the world's biggest pharmaceutical hubs.
- With over 75,000 employees and a market value of around 286 billion dollars, it is one of the largest drug companies on the planet.
- The stock has a beta of 0.42, meaning it has historically been far less bumpy than the broader market. Beta measures how much a stock moves relative to the market as a whole.
- Novartis paid a dividend of about 4.74 dollars per share most recently. A dividend is a cash payment the company sends to shareholders, usually every year.
In the news lately
- A Top Novartis (NVS) Shareholder Says ‘The Party is Over’ for its Dealmaking Team (Yahoo Finance)
- NVS Stock On Track For Worst Week In Over 7 Years After Two Trial Failures In A Week Investor Reportedly Seeks Board Overhaul (Stocktwits)
- Why Novartis (NVS) Stock Is Up Today (Quiver Quantitative)
- Novartis AG (NVS) Stock Up 3.1% but GF Value Says Overvalued GF Score: 68/100 (GuruFocus)
- Novartis AG Stock (NVS) Moved Up by 3.00% on Oct 15: Drivers Behind the Movement (TradingKey)
Follow NVS in your daily brief
Each trading day at 5 PM ET we post what happened to Novartis AG and why it matters, in simple words. Free.
Start my free briefKey terms to know before you follow NVS
Questions about Novartis AG stock
What does Novartis AG do?
Novartis is a giant Swiss drug company. It invents, makes, and sells prescription medicines for serious illnesses like cancer, heart disease, and conditions that affect the brain and immune system. Think of it as a lab that spends years turning science into pills and treatments that doctors prescribe to patients around the world.
Does Novartis pay a dividend?
Yes. Novartis has paid a dividend most recently worth about 4.74 dollars per share. The company has a long history of returning cash to shareholders this way, which is one reason income focused investors pay attention to it.
Where is Novartis based?
Novartis is headquartered in Basel, Switzerland. Basel sits on the Rhine river and is home to several major global pharmaceutical companies, making it one of the most important cities in the drug industry.
Who is the CEO of Novartis?
Vasant Narasimhan has been leading Novartis as CEO. He is a doctor and has focused the company heavily on innovative medicines, particularly in cancer and immunology, moving away from some older business lines.
Is Novartis a big company?
Very. Novartis has a market capitalisation, which is the total value the stock market puts on the company, of around 286 billion dollars. It employs more than 75,000 people across the globe.
What is the ticker symbol for Novartis AG?
Novartis AG trades under the ticker NVS on the New York Stock Exchange.
What is Novartis AG's market cap?
Novartis AG is a mega cap stock with a market cap of about 274.3 billion dollars.
How does Novartis AG make money?
Selling innovative prescription medicines across four core areas: oncology (cancer), immunology, neuroscience, and cardiovascular diseases. Revenue from established, older branded medicines that still hold market share even after their original patent protection has expired. Selling specialized therapies for rarer or more complex conditions, which often command higher prices due to limited treatment alternatives. Generating royalties and licensing income when other companies use Novartis developed compounds or technology under formal agreements.
What moves NVS stock?
Clinical trial results: when a key drug succeeds or fails in trials, the stock can move sharply because future revenue depends on a healthy pipeline of new medicines. Patent cliffs: when a top selling Novartis drug loses its patent, cheaper generic versions flood the market and can cut that drug's revenue fast. Regulatory decisions from bodies like the US FDA, which can approve or reject new drugs and directly affect how much money Novartis can make from years of research spending. Currency swings: Novartis earns revenue across many countries but reports in US dollars, so a stronger dollar can make overseas sales look smaller even if nothing changed in the business.
How can I follow NVS stock every day?
Add NVS to your watchlist on Metric Finance. We post a free brief every trading day at 5 PM ET that explains what happened to the stocks you follow, in simple words.
Similar stocks
Updated October 16, 2026. Educational information, not financial advice. This guide explains the business in general terms and does not include live prices.